Next Quarterly Earnings
Pre-market — typically before 3:30 p.m. German time (before the US open at 9:30 a.m. New York time).
Intellia Therapeutics is a US biotechnology company developing innovative therapeutics using groundbreaking CRISPR/Cas9 genome editing. The company focuses on precise gene editing to treat serious medical conditions.
Pre-market — typically before 3:30 p.m. German time (before the US open at 9:30 a.m. New York time).
Intellia Therapeutics is scheduled to report its next quarterly earnings on 11/05/2026. Pre-market — typically before 3:30 p.m. German time (before the US open at 9:30 a.m. New York time).
Intellia Therapeutics last reported quarterly earnings on 8/6/2026 (Q2 2026). Earnings per share (EPS) came in at -0.80 USD.
Across its last 3 earnings reports, Intellia Therapeutics stock moved by ±10.5% on average the following day. The largest reaction was -22.7% on 11/06/2025; 2 of 3 reactions were positive.
Intellia Therapeutics has beaten analyst EPS estimates in 4 of its last 5 evaluated quarters (beat rate: 80%).
Use the 'Subscribe in calendar' button on this page to add all dates to Google Calendar, Apple Calendar or Outlook. Dates update automatically when they change.
Basis: price reactions to the last 3 report dates (close to close).
Basis: 5 quarters with an analyst estimate and reported EPS.
Past price reactions are not a reliable indicator of future performance.